Aerska

Aerska is a biotechnology company developing RNA interference medicines to treat, delay and prevent diseases of the brain.

The company's antibody oligonucleotide conjugate platform acts as a brain shuttle, enabling RNAi therapeutics to cross the blood brain barrier and reach the central nervous system through systemic administration.

Aerska's initial programmes target genetic forms of Alzheimer's and Parkinson's disease, combining RNA chemistry with data driven patient stratification to guide precision treatment strategies for neurodegeneration.